Rimonabant acomplia, weight loss pill.Rimonabant acomplia, weight loss pill.Information about rimonabant, also known as acomplia or zimulti. Articles
FDA Raises Warning Flags on Over-the-Counter Sale of Low-Dose Xenical
2007-08-23 17:18:00 The U.S. Food and Drug Administration (FDA) staff has raised a variety of warning flags in advance of an advisory committee meeting set for Jan. 23rd to consider GlaxoSmithKline?s petition to sell a half-dose version of the diet drug Xenical (orlistat) without a prescription. The FDA staff, in documents released on Jan. 19th, questioned whether the ... More About: Sale , About , Warning , Counter
Sanofi to Improve ?Communication,? But Not About FDA and Diet Drug Acomplia
2007-08-21 22:27:00 The new chief executive of Sanofi Aventis, Gérard Le Fur, says the company needs to improve its ?communication,? but not by disclosing why diet drug Acomplia (rimonabant) has been stalled for more than a year at the U.S. Food and Drug Administration. Le Fur, the former research chief at Sanofi who took over this month as ... More About: Communication , Diet , About , Improve
Sanofi Presented New Acomplia Data at March 8 2005 Meeting
2007-08-21 22:27:00 Sanofi-Aventis indicated on January 26th that the millions of obese and overweight individuals eagerly waiting for additional information from the clinical trials being conducted for highly publicized Acomplia (rimonabant) are going to have to wait another six weeks for the next update. In a news release that focused largely on the company?s 2004 financial results, Sanofi-Aventis ... More About: Data , About , Sanofi , March
Two FDA Advisory Committees Back Over-the-Counter Sale of Low-Dose Xenical
2007-08-21 22:27:00 Two U.S. Food and Drug Administration (FDA) advisory committees voted on January 23rd to recommend that the regulatory agency approve GlaxoSmithKline?s petition to sell a half-dose version of the diet drug Xenical (orlistat) without a prescription. The FDA advisory committees, following an all-day meeting at which they heard arguments both for and against approving the proposed ... More About: Sale , About , Back , Counter
Sanofi Expresses Confidence Acomplia Will Be Available in U.S. in a Few Mon
2007-08-21 22:26:00 Sanofi-Aventis, developer of Acomplia (rimonabant), told financial analysts on Jan. 30th it is ?very, very confident? it will be permitted to begin selling the highly anticipated weight-loss drug in the United States in the spring of this year. ?We can only report that our collaboration with the FDA is excellent. We have developed the product in ... More About: About , Sanofi , Confidence , Express
Researchers Expected FDA Approval of Alli as Good News for Dieters
2007-08-21 22:26:00 The expected FDA approval later this year of low-dose Xenical (orlistat) as an over-the-counter medication could be good news for consumers struggling to keep their New Year?s resolutions to lose weight, according to an international pharmaceutical research firm. Two FDA advisory committees voted on Jan. 23rd to recommend that low-dose Xenical, be switched from prescription to ... More About: News , Good News , About , Alli , Good
New Acomplia Trial Announced, But Enrollment Said Almost Completed
2007-08-21 22:25:00 A new phase III clinical trial designed to explore whether the weight-loss drug Acomplia (rimonabant) can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk, was announced February 1 by researchers at the University of Rochester Medical Center. Results of previous studies have shown that Acomplia reduces triglycerides and increases HDL ?good? cholesterol, ... More About: About , Trial , Anno
UK Company Plans Trial of Diet Drug With Same Target as Acomplia (Rimonaban
2007-08-21 22:25:00 GW Pharmaceuticals, a U.K. company with an announced goal of being the global leader in prescription cannabinoid medicine, said on Jan. 30 it hopes to soon start a Phase I clinical trial of an experimental diet drug derived from cannabis. The company said researchers had found cannabis not only contains an active ingredient called tetrahydrocannabinol (THC) ... More About: Diet , Company , About , Trial , Plans
Sanofi to Present More Acomplia Data at April 11th Meeting
2007-08-21 22:25:00 Sanofi-Aventis, developer of the highly publicized anti-obesity drug Acomplia, will present new data on the drug?s role in reducing metabolic cardiovascular disease risk factors at a scientific meeting in San Diego April 11th and 12th. Dr. Pierre Rosenzweig, a Vice President of Sanofi-Aventis, will make the presentation at the Annual Metabolic Diseases Drug Discovery World ... More About: Data , About , Sanofi , Present
Most Significant ?Wait Loss? for Diet Drug Acomplia Is Loss of Sanofi?s Hug
2007-08-21 22:24:00 As month after month passes with no sign of imminent FDA action on diet drug rimonabant (Acomplia / Zimulti), the most significant ?wait loss? taking place is loss of the hugh lead Sanofi -Aventis once had in developing a novel approach to weight-loss based on blocking the CB-1 receptors in the brain. A year ago, the French ... More About: Diet , About , Loss , Drug
Marijuana ?munchies? lead to possible diet drug
2007-08-21 22:24:00 The beginning of acomplia rimonabant Mari juana users call them ?the munchies,? those intense food cravings sparked by inhaling the illicit weed?s smoke. Normally blamed for weight gain, these urges to wolf down everything in sight now have led to the development of a drug that may help millions slim down. Called Rimonabant, the experimental pill appears to ... More About: Diet , About , Drug
Rimonabant Acomplia Helps With Weight Loss
2007-08-19 16:58:00 Rimonabant Acomplia Helps With Weight Loss Rimonabant acomplia is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Obesity is now the most common nutritional disorder in western countries. Defined as a body mass index of greater than ... More About: Rimonabant
FDA: Acomplia Rejected as Smoking Cessation Aid
2007-08-19 13:33:00 February 2006 - The U.S. Food and Drug Administration has notified Sanofi-Aventis that its much anticipated drug Acomplia (rimonabant) is ?not approvable? as an aid for smoking cessation, according to the French pharmaceutical manufacturer. No details were immediately provided by either Sanofi or the FDA as to why Acomplia has been rejected as an aid to ... More About: About , Smoking , Rejected
FDA: Acomplia May Be ?Approvable? for Weight Loss, But Not Ready for Market
2007-08-19 13:33:00 The U.S. Food and Drug Administration has notified Sanofi-Aventis that its much anticipated weight-loss drug Acomplia (rimonabant) appears to be ?approvable,? but will not be allowed on the market until certain unspecified conditions are met. The news that the FDA has declined to approve Acomplia came as a severe blow to Sanofi, which had told analysts ... More About: Weight Loss , Weight , Market , About , Loss
FDA Had Bad News on Acomplia for Sanofi
2007-08-19 13:32:00 When the U.S. Food and Drug Administration on Feb. 17th told Sanofi -Aventis that it was going to delay a decision on approving its much anticipated weight-loss drug Acomplia (rimonabant) until certain conditions were met, that was certainly bad news for the French pharmaceutical giant. But until Sanofi sheds some light on the nature of those conditions, ... More About: News , Bad News , About
Analyst Speculation on Acomplia Approval Seen Turning Toward 2007
2007-08-19 13:32:00 February 2006 -Frustrated securities analysts who had been led by Sanofi-Aventis management to believe U.S. FDA approval of weight-loss drug Acomplia (rimonabant) would happen this month now appear to be turning their speculation more toward 2007. The shift from what a week ago seemed like almost universal optimism came as Friday?s announced delay of a final ... More About: About , Analyst , Anal
News About Future of Acomplia Seen Likely on Friday, Feb. 24th
2007-08-19 13:31:00 February 2006 - The next hard news about the future of Acomplia (rimonabant) seems likely to come this Friday , February 24th, when Sanofi-Aventis management meets with financial analysts in Paris to discuss the company?s 2005 financial results. Following Sanofi management?s presentation, top executives will take questions from analysts, and the toughest questions seem certain to focus ... More About: News , Future , About
Diet Drug Acomplia Seen Unlikely to Get FDA Approval for ?Metabolic Syndrom
2007-08-19 13:31:00 If you were hoping that diet drug rimonabant (Acomplia / Zimulti) would be approved for treatment of ?metabolic syndrome? so your insurance company would be more likely to pay for your weight-loss efforts, the current thinking at the U.S. Food and Drug Administration does not appear very encouraging. The FDA?s Metabolic and Endocrine Division has just ... More About: Diet , About
Sanofi Says No New Weight-Loss Trial Needed for Acomplia Approval
2007-08-19 13:31:00 February 2006 - Sanofi -Aventis said on Feb. 22nd that the U.S. Food and Drug Administration has not requested a new trial of the drug Acomplia (rimonabant) prior to possible approval of the highly anticipated drug for use in promoting weight-loss. As a result, Sanofi executives held open the possibility that the drug may still be on the ... More About: Weight Loss , Weight , About , Trial
Is There Any Factual Basis for Sanofi?s Latest Optimism on Acomplia Approva
2007-08-19 13:30:00 Is there any factual basis on which to believe the FDA will approve weight-loss drug Acomplia (rimonabant) for sale in the United States before the end of 2006, or are we once again left only with an optimistic forecast ? and no supporting details ? from the ever-optimistic Sanofi -Aventis management? Well, for a man who was ... More About: About , Optimism
Diet Drug Acomplia Now on Sale in Some Mexican Border Pharmacies
2007-08-19 13:30:00 Diet drug Acomplia (Rimonabant), which remains a considerable distance away from approval by the U.S. Food and Drug Administration, has nevertheless edged a step closer to eager American customers with news that it now can be bought in some pharmacies just across the Mexican border. Several readers of the Acomplia Report have emailed us this past ... More About: Diet , Sale , About
Diet Pill Acomplia Seen Becoming ?Gold Standard? for Treating Obesity
2007-08-19 13:29:00 Diet pill Acomplia (rimonabant), which hasn?t had much good news lately, has been anointed by a leading research firm as the drug that will be the ?clinical gold standard for treating obesity? in 2010. Even though Acomplia / Zimulti remains stalled at the FDA, and in the next few years may face stiff competition from several ... More About: Diet , Gold , Obesity , Standard , About
Diet Drug Acomplia Concerns To Be Aired by FDA Panel in June
2007-08-18 13:32:00 Diet drug rimonabant (Acomplia / Zimulti) will get a full hearing before an independent FDA advisory panel in June , increasing the likelihood that a final decision on whether it will be approved for sale in the United States will come this summer. Sanofi-Aventis announced on March 26th that the pros and cons of the highly anticipated ... More About: Diet , About , Panel , Drug
Few in France to Get Reimbursement for Diet Drug Acomplia (Rimonabant)
2007-08-18 13:32:00 Obese French citizens seeking to buy diet drug Acomplia (rimonabant) will not be reimbursed by the French social security system unless they are type 2 diabetics for whom other treatment has failed. And even then, only 35 percent of the cost of the drug will be covered. The reimbursement conditions, which greatly limit the number of ... More About: Diet , France , About , Drug
Competitor for Diet Drug Rimonabant (Acomplia) Now Has Name: Taranabant
2007-08-18 13:32:00 While Sanofi?s diet drug Rimonabant (Acomplia / Zimulti) remains stalled at the FDA, a potential competitor currently in phase III trials, Merck?s MK-0364, now has an official generic name: Taranabant. Taranabant is Merck?s cannabinoid-1 (CB-1) receptor inverse agonist, and from reports we periodically receive from participants in the phase III trial of this diet drug, taranabant ... More About: Diet , About , Drug
Diet Drug Acomplia (Rimonabant) Approved for Sale in Switzerland
2007-08-18 13:32:00 Diet drug rimonabant (Acomplia / Zimulti) was approved for sale on April 3rd by Switzerland for treatment of obese or overweight patients with at least one type of associated cardiovascular risk. The approval by Switzerland, which is not a member of the European Union, is similar to the EU marketing approval last June, where the drug ... More About: For Sale , Diet , Sale , About
Diet Drug Acomplia (Rimonabant) to Use Name Zimulti in U.S.
2007-08-18 13:31:00 It?s now official. If diet drug Acomplia (rimonabant) is ultimately approved for sale in the United States, the prescription diet pill will go on the U.S. market not as Acomplia but as Zimulti. Sanofi-Aventis, developer of rimonabant which is now sold in a number of European countries, Argentina and Mexico as Acomplia, has long been coy ... More About: Diet , About , Drug , Rimonabant
Diet Drug Rimonabant (Acomplia / Zimulti) Approved for Sale in Brazil
2007-08-18 13:31:00 Diet drug rimonabant (Acomplia / Zimulti) has been approved by ANVISA, the Brazil ian health authority, for sale in Latin America?s largest country, drug-maker Sanofi-Aventis announced on April 26th. Acomplia was approved by Brazil for use ?as an adjunct to diet and exercise for the treatment of obese patients (BMI more than 30) or overweight patients (BMI ... More About: For Sale , Diet , Sale , About
Diet Drug Rimonabant (Acomplia / Zimulti) European Sales Seen Disappointing
2007-08-18 13:30:00 Diet drug rimonabant (Acomplia / Zimulti) sales in Europe in the first three months of 2007 totaled a disappointing 15 million Euros, Sanofi-Aventis announced May 4th, suggesting that widespread European denial of insurance reimbursement is dampening use of the expensive diet pill. Sanofi announced that since Acomplia was launched in Europe last June, the diet pill ... More About: Diet , Sales , About , Drug
Sanofi Explains Why Diet Pill Acomplia Will Be Diet Drug Zimulti in U.S.
More articles from this author:2007-08-18 13:30:00 After more than a year of asking, we now have Sanofi ?s official explanation why diet drug rimonabant ? sold as Acomplia in Europe and the rest of the world ? will be marketed in the United States (if and when it is approved) as Zimulti. According to Hanspeter Spek, Sanofi?s executive vice president for pharmaceutical operations, ... More About: Diet , About , Drug 1, 2, 3, 4, 5, 6 |
|
 |
|
 |
